Stock listing
NASDAQ:ALZN Alzamend Neuro, Inc. Stock
Home listing (NASDAQ) of Alzamend Neuro, Inc.
Follow Alzamend Neuro, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALZN
$1.25 USD +0.04 (+3.3%)
Close on Nov 2, 2026
- Day range
- $1.21 – $1.33 USDNov 2, 2026
- Volume
- 37,062 sharesNov 2, 2026
- Market cap
- $6.03M USDAt the close on Nov 2, 2026 · price × 4.83M shares outstanding
- 52-week range
- $0.84 – $2.61 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $128,628 USDMedian day 37,062 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALZN · Home | $1.25 USD | +0.04 (+3.3%) | 37,062 | $1.32 | $1.33 | $1.21 | $1.21 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:ALZN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.25 | +0.04 | +3.3% | $1.32 | $1.33 | $1.21 | 37,062 | |
| $1.21 | -0.01 | -0.8% | $1.29 | $1.329 | $1.21 | 25,022 | |
| $1.22 | +0.03 | +2.5% | $1.365 | $1.365 | $1.20 | 15,788 | |
| $1.19 | +0.06 | +5.3% | $1.155 | $1.23 | $1.12 | 21,365 | |
| $1.13 | -0.01 | -0.9% | $1.16 | $1.249 | $1.11 | 8,812 | |
| $1.14 | +0.01 | +0.9% | $1.12 | $1.155 | $1.10 | 25,685 | |
| $1.13 | +0.01 | +0.9% | $1.11 | $1.19 | $1.10 | 29,051 | |
| $1.12 | -0.13 | -10.4% | $1.25 | $1.29 | $1.12 | 15,285 | |
| $1.25 | -0.05 | -3.8% | $1.39 | $1.39 | $1.25 | 10,526 | |
| $1.30 | -0.03 | -2.3% | $1.30 | $1.33 | $1.28 | 10,910 | |
| $1.33 | +0.03 | +2.3% | $1.34 | $1.345 | $1.31 | 6,521 | |
| $1.30 | +0.02 | +1.6% | $1.29 | $1.34 | $1.25 | 15,900 | |
| $1.28 | -0.07 | -5.2% | $1.32 | $1.335 | $1.28 | 15,000 | |
| $1.35 | 0.00 | 0.0% | $1.31 | $1.396 | $1.31 | 23,200 | |
| $1.35 | +0.04 | +3.1% | $1.43 | $1.43 | $1.30 | 18,000 | |
| $1.31 | -0.03 | -2.2% | $1.40 | $1.429 | $1.31 | 17,000 | |
| $1.34 | 0.00 | 0.0% | $1.43 | $1.43 | $1.34 | 13,300 | |
| $1.34 | -0.03 | -2.2% | $1.32 | $1.35 | $1.22 | 7,000 | |
| $1.37 | 0.00 | 0.0% | $1.37 | $1.42 | $1.34 | 18,800 | |
| $1.37 | -0.04 | -2.8% | $1.435 | $1.435 | $1.343 | 32,100 | |
| $1.41 | +0.04 | +2.9% | $1.38 | $1.48 | $1.375 | 25,400 | |
| $1.37 | +0.055 | +4.2% | $1.41 | $1.48 | $1.20 | 236,400 | |
| $1.315 | -0.415 | -24.0% | $1.72 | $1.72 | $1.26 | 150,600 | |
| $1.73 | -0.09 | -4.9% | $1.84 | $1.84 | $1.73 | 21,700 | |
| $1.82 | +0.09 | +5.2% | $1.745 | $1.85 | $1.74 | 49,500 | |
| $1.73 | -0.10 | -5.5% | $1.80 | $1.92 | $1.73 | 83,800 | |
| $1.83 | +0.01 | +0.5% | $1.90 | $1.90 | $1.764 | 23,300 | |
| $1.82 | -0.12 | -6.2% | $1.90 | $1.93 | $1.82 | 150,500 | |
| $1.94 | 0.00 | 0.0% | $1.93 | $1.95 | $1.93 | 45,800 | |
| $1.94 | 0.00 | 0.0% | $1.93 | $1.94 | $1.90 | 91,200 | |
| $1.94 | +0.05 | +2.6% | $1.89 | $1.94 | $1.87 | 206,700 | |
| $1.89 | +0.05 | +2.7% | $1.84 | $1.89 | $1.81 | 240,700 | |
| $1.84 | +0.01 | +0.5% | $1.83 | $1.84 | $1.82 | 42,700 | |
| $1.83 | +0.05 | +2.8% | $1.79 | $1.85 | $1.79 | 167,600 | |
| $1.78 | +0.03 | +1.7% | $1.75 | $1.79 | $1.725 | 230,000 | |
| $1.75 | +0.03 | +1.7% | $1.72 | $1.76 | $1.709 | 69,100 | |
| $1.72 | +0.02 | +1.2% | $1.67 | $1.76 | $1.59 | 393,600 | |
| $1.70 | +0.02 | +1.2% | $1.67 | $1.70 | $1.576 | 8,800 | |
| $1.68 | 0.00 | 0.0% | $1.69 | $1.73 | $1.645 | 29,600 | |
| $1.68 | +0.02 | +1.2% | $1.66 | $1.717 | $1.62 | 31,200 | |
| $1.66 | -0.04 | -2.4% | $1.70 | $1.73 | $1.65 | 63,200 | |
| $1.70 | 0.00 | 0.0% | $1.65 | $1.72 | $1.65 | 128,200 | |
| $1.70 | +0.063 | +3.8% | $1.65 | $1.70 | $1.565 | 100,700 | |
| $1.637 | +0.037 | +2.3% | $1.615 | $1.68 | $1.615 | 23,300 | |
| $1.60 | -0.06 | -3.6% | $1.655 | $1.655 | $1.51 | 37,700 | |
| $1.66 | -0.005 | -0.3% | $1.64 | $1.72 | $1.64 | 242,100 | |
| $1.665 | -0.005 | -0.3% | $1.67 | $1.67 | $1.65 | 39,700 | |
| $1.67 | +0.07 | +4.4% | $1.59 | $1.67 | $1.55 | 125,300 | |
| $1.60 | +0.05 | +3.2% | $1.53 | $1.65 | $1.501 | 122,000 | |
| $1.55 | -0.01 | -0.6% | $1.51 | $1.58 | $1.41 | 133,800 | |
| $1.56 | -0.07 | -4.3% | $1.57 | $1.598 | $1.49 | 242,700 | |
| $1.63 | +0.11 | +7.2% | $1.56 | $1.67 | $1.532 | 486,200 | |
| $1.52 | 0.00 | 0.0% | $1.50 | $1.60 | $1.50 | 95,100 | |
| $1.52 | -0.06 | -3.8% | $1.52 | $1.576 | $1.51 | 37,500 | |
| $1.58 | +0.03 | +1.9% | $1.531 | $1.59 | $1.481 | 118,600 | |
| $1.55 | +0.09 | +6.2% | $1.46 | $1.55 | $1.445 | 87,500 | |
| $1.46 | +0.02 | +1.4% | $1.43 | $1.46 | $1.414 | 25,200 | |
| $1.44 | -0.02 | -1.4% | $1.455 | $1.46 | $1.41 | 19,700 | |
| $1.46 | 0.00 | 0.0% | $1.46 | $1.46 | $1.46 | 16,400 | |
| $1.46 | +0.09 | +6.6% | $1.38 | $1.46 | $1.38 | 27,700 | |
| $1.37 | -0.01 | -0.7% | $1.38 | $1.421 | $1.35 | 18,100 | |
| $1.38 | -0.05 | -3.5% | $1.42 | $1.45 | $1.33 | 59,400 | |
| $1.43 | -0.02 | -1.4% | $1.42 | $1.45 | $1.38 | 43,400 | |
| $1.45 | +0.11 | +8.2% | $1.38 | $1.45 | $1.34 | 149,500 | |
| $1.34 | +0.03 | +2.3% | $1.30 | $1.35 | $1.29 | 28,500 |
- Ticker
- NASDAQ:ALZN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Aug 20, 2026
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Latest deck · Sep 29, 2026
ISMRM Workshop Advances in X-Nuclei MR 2026
Conference · 17 slides
Latest news
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Aug 20, 2026
Closed $1.63 (+7.2%) on Aug 20, 2026
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Aug 4, 2026
Closed $1.45 (+8.2%) on Aug 4, 2026
Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)
Jul 22, 2026
Closed $1.26 (-6.7%) on Jul 23, 2026
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Apr 7, 2026
Closed $0.927 (-2.4%) on Apr 7, 2026
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Mar 26, 2026
Closed $1.50 (-22.3%) on Mar 26, 2026
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Mar 16, 2026
Closed $2.10 (+2.9%) on Mar 16, 2026
Financings
Series D Convertible Preferred Stock
Aug 4, 2026
Tranche closed: US$7.5M raised · US$1,000 a share
Buyers: Ault Lending, LLC (agreed to purchase up to 25,000 Preferred Shares for $25,000,000; purchased 7,500 Preferred Shares for $7,500,000 at the initial closing)
Use of proceeds: General working capital and corporate purposes, including furthering its clinical trials
Decks
ISMRM Workshop Advances in X-Nuclei MR 2026
Conference · 17 slides · Sep 29, 2026
Investor Presentation (July 2026)
Investor deck · 29 slides · July 2026
Investor Presentation (May 2024)
Investor deck · 30 slides · May 15, 2024
Investor Presentation (April 2023)
Investor deck · 28 slides · Apr 25, 2023
Alzamend Neuro, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 72 in all · newest Aug 20, 2026 · oldest 2021
- Decks
- 11 decks · latest Sep 29, 2026
Where Alzamend Neuro, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALZN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALZN | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Alzamend Neuro, Inc.